TipRanks
Go Ultimate55% OFF

Origin Agritech (39O1) AI Stock Analysis

DE:39O1

Origin Agritech

(Stuttgart:39O1)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Cost restructuringThe sharp reduction in operating expenses and narrower net loss indicate that restructuring is producing measurable operating leverage. If maintained, a leaner cost base can reduce the revenue scale required for breakeven and preserve resources for sales, R&D, and commercialization.
Negative Factors
Revenue and profitability deteriorationThe revenue contraction and continued gross-profit compression show that the commercial transition has not yet produced sufficient scale. Persistent losses reduce internal funding capacity and make earnings less predictable, leaving future improvement dependent on successful product adoption and sales execution.

Origin Agritech (39O1) vs. iShares MSCI Germany ETF (EWG)

-60%-50%-40%-30%-20%-10%0%10%20%DE:39O1-44.96%EWG+4.43%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
EUR 10.94M
Dividend Yield
―
Average Volume (3M)
10.68K
Price to Earnings (P/E)
-0.8
Beta (1Y)
0.65
Revenue Growth
-27.22%
EPS Growth
-870.11%
Country
Germany
Employees
97
Sector
Basic Materials
Sector Strength
61
Industry
Agricultural Inputs

Origin Agritech Business Overview & Revenue Model

Company Description

Established in 1997 and headquartered in Beijing, China, Origin Agritech Limited is a Chinese firm operating in two primary areas: agricultural biotechnology and an e-commerce platform. Its biotechnology segment focuses on the genetic enhancement and...

Origin Agritech Earnings Call Summary

Earnings Call Date:May 20, 2026(Q2-2026)|% Change Since:-25.65%|Next Earnings Date:Jan 10, 2027
Earnings Call SentimentNeutral

The call presented a balanced view: clear operational and structural progress (large cuts in G&A, improved operating loss, strengthened biotech credentials, rebuilt sales force, sizable breeding pipeline and targeted variety acquisitions) alongside meaningful near-term challenges (a 31.9% revenue decline, ongoing net loss, modest cash position, higher inventories and dependency on regulatory timing for GMO commercialization). Management emphasized that the company is in the midpoint of a recovery plan and investing in sales and R&D to convert pipeline into revenue, but realization of that upside remains contingent on execution and policy developments.

Positive Updates

Strategic Restructuring Showing Early Financial Impact
Total operating expenses fell to RMB 18.4M in H1 FY2026 from RMB 32.8M prior year, a 43.9% reduction, driven by a 69.8% decline in general and administrative expenses (RMB 25.0M to RMB 7.6M). Loss from operations improved to RMB 12.9M vs RMB 24.7M prior year (47.8% reduction) and net loss attributable improved to RMB 14.4M from RMB 25.6M (43.8% improvement).

Negative Updates

Significant Revenue Decline
Total revenues for H1 FY2026 were RMB 49.2M (USD 7.1M) vs RMB 72.3M prior year, a decrease of approximately 31.9%, driven primarily by a strategic shift from external seed tolling services toward new corn seed product sales.

Company Guidance

The explicit guidance from management was that operating leverage is becoming visible and the company expects the rebuilt foundation to convert into commercial outcomes by the first half of fiscal 2027, with a longer‑term goal of becoming a top‑3 Chinese corn seed company by 2030–2032; near‑term execution metrics cited include a 36‑person sales force deployed against KPI contracts with six regional sales companies under the Aoyun 2026 program, spring planting field activity underway, and commercialization readiness with a BBL2‑2 biosafety certificate, two crop seed production licenses and a restored Xinjiang processing facility. Financially, management is prioritizing intentional investment in selling and marketing (S&M up 93.3% to RMB 5.1m) and steady R&D (up 11.1% to RMB 5.7m) while driving cost discipline (total OPEX down 43.9% to RMB 18.4m, G&A down 69.8% to RMB 7.6m), with revenues of RMB 49.2m (‑31.9% YoY), gross profit RMB 5.5m, operating loss narrowing to RMB 12.9m (‑47.8% YoY) and net loss improving to RMB 14.4m (‑43.8%), cash RMB 13.4m, inventories RMB 24.8m, short‑term borrowings RMB 9.5m and total liabilities RMB 168.1m; R&D pipeline metrics highlighted include >30,000 winter test‑cross combinations, >10,000 new combinations added to the test pipeline, Hi3 platform use and AI models leveraging >200,000 germplasm resources.

Origin Agritech Risk Analysis

Origin Agritech disclosed 53 risk factors in its most recent earnings report. Origin Agritech reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Origin Agritech Peers Comparison

Overall Rating

UnderperformOutperform
Sector (61)

Financial Indicators

DE:39O1 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *61Neutral$10.43B7.12-0.05%2.87%2.86%-36.73%
BHSTBHST52Neutral$37.63M-3.07-58.30%―17.50%24.63%
AVDAVD44Neutral$32.45M-0.58-27.83%―-3.54%56.67%
RKDARKDA39Underperform$380.41K-0.02-339.85%―-12.24%17.56%
BIOXBIOX34Underperform$13.15M-0.06-216.09%―-26.10%14.85%

* Basic Materials Sector Average

Performance Comparison

-75%-50%-25%0%DE:39O1AVDRKDABHSTBIOXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
DE:39O1 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:39O1Origin Agritech0.71-0.72-50.35%
AVDAmerican Vanguard Corporation1.10-3.57-76.45%
RKDAArcadia Biosciences Inc.0.16-3.45-95.65%
BHSTBioharvest Sciences, Inc.1.66-7.59-82.05%
BIOXBioceres Crop Solutions0.21-1.65-88.82%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.